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Abstract
We recently described a set of drug-like molecules obtained from an in silico screen that stabilize
mutant superoxide dismutase-1 (SOD-1) linked to familial amyotrophic lateral sclerosis (ALS)
against unfolding and aggregation but exhibited poor binding specificity towards SOD-1 in presence
of blood plasma. A reasonable, but not a conclusive model for the binding of these molecules, was
proposed based on restricted docking calculations and site-directed mutagenesis of key residues at
the dimer interface. A set of hydrogen bonding constraints obtained from these experiments were
used to guide docking calculations with compound library around the dimer interface. A series of
chemically unrelated hits were predicted, which were experimentally tested for their ability to block
aggregation. At least six of the new molecules exhibited high specificity of binding towards SOD-1
in presence of blood plasma. These molecules represent a new class of molecules for further
development into clinical candidates.
Introduction
Protein misfolding diseases such as Alzheimer's disease, Parkinson's disease, Huntington
disease, Familial polyneuropathy, Gaucher's disease and amyotrophic lateral sclerosis (ALS)
are related to aggregation of proteins often caused by loss of protein stability 1-5. Point
mutations - the most common cause of human genetic diseases - can inhibit correct folding
and assembly of the protein, cause mistrafficking in the endoplasmic reticulum and in the
majority of cases aggregation into toxic structures 1-5. These diseases can occur with the wild-
type proteins, as mutations are not absolutely required, although mutations can often accelerate
the onset of diseases. Traditional approaches of ‘function based screening’ and drug
development are not generally applicable to these protein misfolding diseases since such
approaches are designed to screen for antagonistic ligands6-8. Although small molecule
enzyme inhibitors in some cases have been shown to stabilize proteins against misfolding, they
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also interfere in enzyme function 9,10. Pharmacological chaperones are small molecules that
can bind to their protein target and function to either inhibit aggregation, block mistrafficking
and/or protect cells from death without interfering with normal protein function1,9,11-16.
Though osmolytes have been shown to function as general chemical chaperones12-14, there is
also precedence for small molecules as specific pharmacological chaperones in the case of
familial amyloid polyneuropathy (FAP), caused by mutations in the gene encoding
transthyretin (TTR) and Gaucher's disease, caused by misfolding of glucocerebrosidase 6,
8-10,17-23. Many FAP mutations destabilize the native TTR tetramer, facilitating its
dissociation, partial unfolding, and aggregation. The natural ligand of TTR, thyroxine,
stabilizes the tetramer and prevents its aggregation in vitro. Drug-like molecules that are
thyroxine analogs bind and stabilize the native TTR tetramer, preventing its aggregation in
vitro 6,8,17-21. These compounds could potentially be used for the treatment of FAP. Similarly,
mutations in glucocerebrosidase lead to misfolding and mislocalization of the protein in vivo.
Inhibitors of this enzyme have been shown to significantly stabilize the protein and lead to
correct subcellular localization 23. In this manuscript, we describe a methodology for improving
binding specificity of pharmacological chaperones for targeting novel binding sites on
superoxide dismutase-1 (SOD-1), which has been linked to familial ALS.
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, is a fatal motor neuron disease
that affects > 50,000 Americans and many more individuals worldwide. Though most ALS
cases are sporadic with no genetic disposition, a small percentage of patients carry point
mutations in the gene-encoding SOD-1, a β-sheet-rich dimeric metalloenzyme that is normally
responsible for scavenging superoxide ions24. Familial ALS (FALS) does not appear to arise
from a loss of this important activity but rather from a “gain of toxic function” due to
aggregation of the mutant form of SOD-1. There are 114 known SOD-1 FALS mutations,
which are distributed throughout the primary sequence and tertiary structure25. It is proposed
that these mutations affect the structural stability of SOD-1. One or more FALS SOD-1
mutations have been linked to decreased metal binding, decreased formation of a stabilizing
intramolecular disulfide, decreased structural stability, and increased propensity to
monomerize and aggregate26-38. Though the consequences of the mutations may differ, the
common underlying factor in all cases is the loss of thermodynamic stability29,34,39-43.
Analyzing a number of mutants in simulation studies revealed long range effects of widely
distributed mutations on the stability of the dimer interface of SOD-140,44,45.
Though increasing metallation as a strategy to preserve stability has been suggested as a
therapeutic approach46-48, we have pursued an alternate strategy to inhibit SOD-1 aggregation
with small drug-like molecules, which act as pharmacological chaperones 47,49. Although no
natural ligands are known for SOD-1, we have recently described a number of drug-like
molecules identified from an in silico screen (docking calculations), which bind at the dimer
interface and stabilize SOD-1 against aggregation and unfolding 50. Potent inhibition of SOD-1
aggregation, though necessary, is not sufficient for efficacy in humans. An ideal drug molecule
should be specific for SOD-1 and have low binding specificity towards other human proteins
in order to reduce toxic side-effects51. In this manuscript, we use a series of structurally related
compounds and mutagenesis of the protein to arrive at a model for compound binding, and use
structural features (docking constraints) derived from this model to identify novel compounds
from a database with improved ADME properties. A general outline for the strategy used in
this manuscript to identify new compounds based on existing hits is shown in supplemental
figure 1. The preliminary structure-activity relationship from this investigation can be utilized
for further optimization of the pharmacological chaperones.
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Materials and Method
Chemicals and reagents
All solvents, chemicals and protein purification reagents, unless otherwise stated, were
commercially available, were of the best grade, and were used without further purification.
Synthesis and characterization of 14, 13 and 14 is described in the supporting information
section. All compounds used in this study were homogeneous (purity of not less than 98%),
as determined by high-performance liquid chromatography (HPLC).
Cloning, purification and enzymatic activity
Genes encoding human SOD-1, WT and A4V, were cloned by a PCR strategy into pGex6P1
(Amersham) using the BamH1 and Xho1 restriction sites of the vector. SOD-1 was expressed
as a glutathione-S-transferase (GST) fusion in the Rosetta E.coli strain (Novagen). Purification
of SOD-1 and its mutants was carried out as described previously52. The superoxide dismutase
activity of purified SOD-1 and the mutants was measured by a coupled enzyme assay using
xanthine oxidase to generate superoxide. SOD-1 activity was measured colorimetrically with
(2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide).
Preparation of apo-protein and ICP-MS analysis
Metal-free SOD was generated by repeated dialysis (5 times) against 100mM acetate buffer
pH 3.8 and 10mM EDTA. Following this dialysis, the sample was dialyzed against 100mM
acetate buffer pH 5.5 containing 100mM NaCl 5 times to remove EDTA from the sample. All
buffers used in this experiment except the ones containing EDTA were passed over 250ml of
chelex 100 resin to ensure complete removal of any trace copper or zinc in the buffer.
Aggregation assay was carried out in plastic tubes rather than glass vials to prevent introduction
of stray copper or zinc into the sample. The compounds used for this analysis were diluted
from their stock solutions into chelex 100-treated water prior to their addition into the
aggregation assay.
Quantitative metal analyses of apo-protein samples were conducted using a Perkin Elmer
6100DRC ICP-MS. Sample aspiration into the ICP-MS was through a quartz Meinhard
concentric nebulizer and a cyclonic spray chamber. Gas flow was set at 1.08, 1.225 and
18.5L·min-1 for the nebulizer, auxiliary and plasma flows respectively and the incident R.F.
power was set at 1250 Watts. The instrument was tuned using a 10ng·mL-1 solution of Li, Mg,
Ce, Co, In, Ba and U to minimize oxide adduct formation and doubly charged species without
unduly compromising sensitivity. Count rates were typically better than 600× 103 cps
for 115In with a RSD of <0.5%. The Ce:CeO ratio was typically < 0.02 under these operating
conditions.
Protein solution extracts together with appropriate buffer and dialysis reagent blanks were
diluted 3 × using 2% HNO3 prepared in 18μ Ohm water containing 10 μg·L-1 of gallium. The
gallium was used as an internal standard to correct for changes in instrumental sensitivity,
sample viscosity and aspiration rate during ICP-MS analysis. Acid blanks containing gallium
were prepared in a similar manner. Data acquisition was conducted in the peak-hopping mode.
Five readings were taken per sample with a dwell time of 100msec·amu-1 and 20 sweeps per
reading. The Zn and Cu content of each sample was quantified from response curves generated
for 64Zn, 66Zn and 68Zn, 63Cu and 65Cu from a dilution series of certified metal standard
solutions of known concentration. Linear responses (r2 > 0.999) were observed over a dynamic
range of four orders of magnitude of metal concentration. Individual analyses of the standards,
acid blanks and samples were corrected for variations in the response for the internal standard,
and the content of metal in each sample was corrected for dilution and normalized for protein
concentration after subtraction of the acid blank. Highly comparable values were obtained for
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the other isotopes analyzed, indicating minimal interference effects from the matrix (data
from 64Zn and 65Cu responses shown). Overall, accuracy was confirmed by the analysis of
five independent replicate samples of certified standards and was better than ± 3%. Detection
limits, as determined by the values obtained from the analysis of multiple acid blanks, were
better than 0.2 μg·L-1 for Cu and Zn.
Database preparation and Docking
All computations were carried out on an 16-node Beowulf Cluster (each node∼ 3.0Ghz quad-
core Xeon processor) running RedHat Linux (http://www.redhat.com). Structure data files for
small molecules from 11 commercially available databases were consolidated and filtered to
remove duplicates. These molecules are from updated versions of the same databases that we
used in our previous publication50. 2.2 million molecules consolidated from these databases
were treated with the ligprep module of Schrödinger First Discovery Tool (Schrödinger Inc.)
to remove counter ions, adjust charge states and generate tautomers wherever applicable. The
final database was stored in maestro (Schrödinger Inc. proprietary format). The protein was
prepared for docking using the protein prep utility of GLIDE. Following removal of water
molecule coordinates from the first dimer in the asymmetric unit SOD-1A4V structure
(1UXM.pdb), hydrogen atoms were added using the applyhtreat suite of GLIDE and energy
minimized using the OPSLAA forcefield. Positions of hydrogen bonds in the structure were
refined using the Schrödinger protassign utility. The protassign utility simply uses a set of
rules to generate an optimal hydrogen bonding network in the structure in order to resolve
ambiguity in protonation of residues such as histidine. Residue 148 was chosen as the center
of mass for generation of a 20Å grid for docking calculations. The program Glide (part of the
Schrödinger First Discovery Suite) was used for docking. The first main docking job was
carried out using the default Glide parameters. The default glide parameters allow for flexible
ligand docking but not flexible protein. In case of constrained docking, hydrogen constraint
parameters were placed on Val 7 and Asn 53 prior to grid calculations. The desired number of
hydrogen bonds was selected at the time of actual docking. To facilitate computation, the main
job was split into subjobs using the paraglide utility to allow for parallel processing on the
linux cluster. The results obtained from the first round of docking were docked again using the
Glide extra precision mode which exacts severe penalties for complexes that violate established
principles, including ligand stereochemistry, and solvent exposure of charged groups. The
results of docking were analyzed using the pose viewer utility built into Glide. Shape
comparison was carried out, which evaluates integral overlap between the compounds.
Gel filtration and aggregation assay
Dimeric SOD-1 was purified on a superdex 75 (16/60) gel filtration column (Pharmacia) to
produce starting material for each aggregation experiment. Incubation was performed at 37°C
and aliquots were periodically removed and analyzed by gel filtration on a superdex 200
(3.2/30) gel filtration column (Pharmacia). All chromatography was performed in TBS (20
mM Tris pH 7.4, 150 mM NaCl) on a Waters 2695 Alliance HPLC, and monitored at 220 nm
and 276 nm. 5mM EDTA was added to induce aggregation prior to incubation at 37°C. In order
to test the effect of compounds on aggregation, 75μM of compound was added to 25μM of
apoprotein and incubated at 37°C for 15 min. Following this incubation period, 5mM EDTA
was added to initiate aggregation. To test the effect of compound concentration, samples were
prepared as above with increasing concentrations of compounds and aggregation was allowed
to proceed for 4 hrs prior to analysis. Samples were analyzed using size exclusion
chromatography and amount of dimer was estimated from area under the peak. Percentage
inhibition was calculated using the differences between the untreated A4V samples and
samples treated with various compound concentrations.
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Guanidinium chloride unfolding
Equilibrium unfolding transitions, as a function of GdnCl concentration, were monitored by
circular dichroism spectroscopy. SOD-1 samples with compounds (50μM) at a final
concentration of 12μM in 20mM Tris (pH 7.4) / 150mM NaCl were equilibrated over a range
of GdnCl concentrations from 0 - 5M at 0.2M intervals. Far UV CD spectra were recorded to
measure changes in secondary structure content as a function of GdnCl concentration.
The slit width was 5 nm for both monochromators. Each measurement was an average of five
readings. The data were analyzed directly for a two-state (N← →U) transition as follows: the
raw data for the GdnCl-induced denaturation studies were converted to fractions of the protein
in the unfolded state (fu) as a function of GdnCl concentration using the equation:
where Y0 is the observed spectroscopic property, Yf and mf are the slope and intercept of the
folded state baseline and Yu and mu represent the respective values of the unfolded baseline.
The folded fraction was calculated as (fn = 1-fu) and the equilibrium constant was determined
by Keq = fu/fn. The free energy of unfolding was determined using the equation ΔG = -RT ln
(Keq) where T is the temperature in Kelvin and R is the universal gas constant (1.987 cal
mol-1 K-1).
CSF and plasma selectivity assay
GST-SOD fusion protein or GST (tag) at a final concentration of 75μM was added to 1 ml of
human blood plasma or CSF and incubated with 100μM of the various compounds. This
mixture was incubated on an orbital shaker at 60 rpm and 4°C for 24 hrs. A 1:1 gel/slurry (250
μl) of glutathione-sepharose (GE bioscience) was added to the solution and incubated on a
gentle rocker at 20 rpm and 4°C for 1 h. The solution was centrifuged (16,000 × g) and the
supernatant was discarded. 150μl of pre-chilled 5% TFA solution was added to the beads and
incubated on a gentle rocker for 2 hrs. The samples were centrifuged (16,000 × g) and the
supernatant was removed and split into batches of 50μl. The supernatant elution samples from
the beads were directly loaded onto a Waters Alliance 2690 HPLC using an autosampler. The
entire sample was injected for a single analysis and separated on a C18 reverse-phase column
using a 40-100% gradient of solution B over 20 min (solution A: 94.8% water/5% acetonitrile/
0.2% trifluoroacetic acid; solution B: 94.8% acetonitrile/5% water/0.2% trifluoroacetic acid).
Pure compound was injected at a concentration of 25μM to obtain retention time in each case.
A buffer control without blood plasma was treated the same way with the compounds and
evaluated for compound binding.
α-synuclein aggregation assay
Samples of α-synuclein were dissolved in 50mM Tris-HCl (pH 8.0) and filtered through a
Millipore Microcon 100K MWCO filter. Equimolar amounts of DJ-1 samples and α-synuclein
were diluted to a final concentration of 20μM in 50mM Tris-HCl, pH 8.0 / 3.1% 1,1,1,3,3,3-
hexafluoroisopropanol (HFIP). Aggregation was initiated by incubating the samples at room
temperature with roller agitation. 1mM stock solution of thioflavin T (thio T, Sigma) was
filtered through a 0.2-μm polyether sulfone filter and added to the sample wells at a final
concentration of 20μM and incubated for 1 min prior to recording of fluorescence. Fluorescence
was monitored at 490nm by an Analyst 96-384 plate reader (LJL Biosystems). Fluorescence
readings were obtained at 5 min intervals for 1 h. Data points from three independent
experiments were used for averaging and calculation of error bars. For testing compounds,
samples of α-synuclein were dissolved in 50mM Tris-HCl and incubated with the small
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molecule at a final concentration of 100μM and pre-incubated on ice for 30 min prior to the
addition of HFIP.
Results
Binding of small molecule to SOD-1 bearing aza-uracil and uracil sub-structures in buffer
and blood plasma
Analysis of the hits obtained from the initial in silico screen 50 revealed four molecules that
bear either a uracil or an aza-uracil substructure. Eleven new commercially available molecules
(Supplementary figure 2) bearing both sub-structures and linkers were tested for their ability
to block mutant SOD-1 aggregation (Figure 1a). The familial mutant, SOD-1A4V, was chosen
for the aggregation assay since it is known to aggregate rapidly compared to other SOD-1
mutants at low protein concentrations. 25μM metal deficient SOD-1A4V (prepared using a
method described previously) was allowed to aggregate in the presence of 75μM of small
molecules and analyzed over size exclusion chromatography for aggregation kinetics. 5mM
EDTA was also added to accelerate aggregation. SOD-1A4V aggregates rapidly, with greater
than 50% of dimer lost within the first four hours of incubation at 37°C. Exceptionally good
inhibitors led to less than 20% loss of dimeric SOD-1A4V over a period of 48 hrs, whereas poor
inhibitors (or non-inhibitors) had no effect on accelerated aggregation. Seven molecules (1, 2,
3, 7, 8, 9 and 10) out of the eleven were found to be strong inhibitors of SOD-1 aggregation at
a concentration of 75μM (Figure 1a). In general, it was observed that large molecules such as
11, which has greater solvent exposure and lacks conformational flexibility, were poor
inhibitors of aggregation.
The aggregation assay is sensitive enough to distinguish non-stabilizers from stabilizers, but
it cannot accurately measure the differences between the seven stabilizers. We measured the
effects of these compounds on the chaotrope-induced (GdnCl) denaturation of A4V. This
appeared to be a valid approach in absence of a direct assay for measuring dimerization of A4V
or binding of ligand. A4V (12 μM) was incubated with compound (50 μM) and increasing
concentrations of GdnCl. Far-UV circular dichroism signal was measured as function of
[GdnCl]. Typical transition curves for GdnCl-induced unfolding are shown in Figure 1b. In
these curves, the straight lines indicate the pre-transition and post-transition regions of
unfolding. The data were analyzed directly, assuming a two-state (N→U) transition, and
thermodynamic properties were measured by fitting the data to a linear extrapolation model
53. The stabilization of A4V in the presence of the compounds was expressed as ΔG values,
listed in Table 1.
The strongest SOD-1 aggregation inhibitors in buffer may not necessarily function well in
biological fluids such as blood plasma or cerebrosipinal fluid (CSF), primarily due to
competition from large amounts of plasma proteins such as blood plasma albumin. The top
seven SOD-1 stabilizers were evaluated for their ability to bind a GST-SOD-1 fusion protein
relative to the rest of the proteins in blood plasma. Similar approaches have been used by Kelly
and co-workers to obtain chemical chaperones for blocking transthyretin aggregation (involved
in FAP) in human plasma. While their assays used a specific antibody towards TTR, we used
a fusion protein in our investigation. Both assays work on very similar principles 54-56. SOD-1
dimer (Kd in nM range) is a substantially stronger dimer compared to GST (Kd in μM range)
and therefore the solution dimer will be dictated by SOD-157,58. It is reasonable to assume that
the dimer interface cavity of SOD-1 will be intact and not affected by the GST tag. Briefly,
GST-SOD fusion protein was added ex vivo to blood plasma and incubated with the various
compounds (see materials and methods for details). The GST-SOD-drug complex was isolated
using glutathione beads and analyzed using reverse phase HPLC after liberating compound
from the complex using 5% TFA. A buffer control (no blood plasma) treated in an identical
fashion was taken as the theoretical maximum in each case for calculating relative binding.
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For blood plasma binding, any molecules having greater than 50% binding specificity were
categorized as a highly specific binder. Control experiments were also carried out where
compound binding to GST (tag) in buffer was measured in an identical fashion. None of the
molecules exhibited any specific binding affinity towards GST (Figure 1c). This ruled out the
possibility of interference or competition towards compound binding to GST-SOD-1 from the
tag. All seven molecules tested by this assay showed relatively poor binding selectivity towards
the GST-SOD-1 fusion protein as shown in Figure 1c.
Modeling of aza-uracil and uracil based inhibitors and mutational analysis of the binding site
Non-specific binding to human proteins other than SOD-1 in blood plasma and/or CSF may
lead to off-pathway toxicity; therefore it is necessary to obtain molecules with minimal binding
to blood plasma and CSF proteins in order to be a viable lead compound. In order to improve
the selectivity of the molecules, it is necessary to understand the interactions of these molecules
with the protein in detail. The top seven aggregation inhibitors from the assays above were
docked into the dimer interface cavity around residue 148 (20Å grid) using the program GLIDE
v2.5. Control calculation was also carried out using a much larger grid (38Å), which included
almost 90% of the protein. The molecules still preferentially bound at the dimer interface
despite the bigger grid. A second set of control docking calculations were carried out where
the molecules were “forced docked” using a 20Å grid around residue F45 (supplementary
material 5). The scores obtained from these control calculations were significantly lower than
those obtained from docking at the dimer interface (supplementary material 6). This docking
calculation revealed that the molecules preferentially bound at the dimer interface cavity. The
modeling results show that the aza-uracil substructure appears to occupy roughly the same
position within the protein dimer interface with r.m.s deviation between the poses being <1.3Å
(Figure 2a). The side-chains however do not appear to have any preferred orientation (Figure
2a). The dimer interface cavity of SOD-1 is composed of hydrophobic residues such as Val
148 and Val 7 with a small number of peripheral charged or polar residues such as Lys 9 and
Asn 53. The pocket is symmetric in nature, with similar side chain orientation for residues on
either side. The model indicates the possibility of a hydrogen bond between N3 of either uracil
or aza-uracil substructure with the backbone carbonyl oxygen of Val 7 in the majority of the
cases (Figure 2a). Similarly, a hydrogen bond was observed between N5 and the side chain
carbonyl Asn 53 (Figure 2a). The Val 148 residue from either subunit provides a “hydrophobic
base” for proper orientation of the aromatic rings. In order to test the importance of these
residues to compound binding, Val 148 and Asn 53 were mutated to Ala using site-directed
mutagenesis. Each of these mutations independent of each other led to complete loss of
compound binding (Figure 2b), indicating that the presence of both these residues at the dimer
interface is critical for compound binding. The mutant SOD-1A4V/N53A and
SOD-1A4V/V148A showed CD spectra and secondary structure content similar to showed
SOD-1A4V. Unfolding of the double mutants using GdnCl. showed only a slight change in
stability when compared to SOD-1A4V (Figure 1b). This is not surprising since effects of
mutations are often not additive in terms of free energy of destabilization59.
In conjunction with the mutagenesis experiments, two compounds (4 and 5) were tested for
their ability to block aggregation (Figure 1a). These two molecules are methylated either at N3
position of the ring nitrogen (4) or at the N5 ring nitrogen (5), which would disrupt the hydrogen
bonds with Asn 53 and Val 7. Neither compound blocked aggregation of SOD-1A4V under
demetallating conditions as described above (Figure 1a). This further supports that the nitrogen
rings may be involved in critical hydrogen bonds with the protein.
Three new compounds (12, 13 and 14) were synthesized bearing two aza-uracil or uracil
substructures but different linker lengths. The purity of these molecules were determined to be
not less than 98% using reverse phase HPLC analysis. It was reasoned from the modeling of
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12 that having two identical pharmacophores may improve binding since symmetric
compounds may be able to make two pairs of hydrogen bonds on opposite subunits (Figure
2c). Three symmetric versions of the inhibitors were synthesized where two aza-uracil
pharmacophoric groups were joined using linkers of various lengths. The molecules were
analyzed for their chemical identity using NMR and for purity on reverse-phase HPLC analysis
(see supporting information). The three new molecules (12, 13 and 14) were all found to be
strong inhibitors of SOD-1A4V aggregation (Figure 1a). A dose-response study comparing 8
and 12 revealed that 12 was significantly more effective in blocking aggregation compared to
8 (Figure 2d), supporting the proposed model for compound binding. It was expected that this
class of molecules might have better binding specificity towards SOD-1, however they still
exhibited poor binding selectivity towards GST-SOD-1 in blood plasma (Figure 1c). These
results suggest that it might be hard to proceed towards drug development with the aza-uracil
candidates since only minimal modifications can be made to the base pharmacophore without
compromising binding. However, it was reasoned that the structural information derived from
the experiment above could be used as input into docking calculations to identify better lead
molecules.
Docking of ligand and virtual screening of a chemical library using an improved scoring
function from experimentally derived constraints
Though a detailed description of the GLIDE methodology (Grid-based Ligand Docking with
Energetics) is beyond the scope of this manuscript, briefly, the GLIDE algorithm approximates
a systematic search of positions, orientations and conformations of the ligand in the receptor
binding site using a series of hierarchical filters. The shape and properties of the receptor are
represented on grids that are computed prior to docking. In absence of any experimental input,
the grid is considered unconstrained and the ligands are placed and scored based on shape, size
and chemical features of the molecules. In cases such as SOD-1, where no x-ray structure of
bound ligand is available for a starting model, GLIDE leads to database enrichment by
eliminating molecules that are too big or small (shape driven). However, it can lead to
inaccurate ranking of molecules and often enriches false positives. This was observed in our
original docking calculations where only 15 out of 100 molecules that were active did not rank
order well by docking score 50. However, if experimentally derived constraints such as
hydrogen bonds and electrostatic interactions are included as part of the docking grid
calculations, that should, in principle, improve the performance of the scoring function for
ranking active ligands. In order to optimize the docking parameters, the experimentally verified
SOD-1 stabilizer, 12, was combined with a set of 20 “false positive” molecules to develop a
“training set”. The “false positives” are defined as molecules that bear a very similar shape to
the active molecules but do not necessarily share the same capability to bind (e.g. can not form
hydrogen bonds) and found to be poor inhibitors of SOD-1 aggregation experimentally
(supplemental figure 3). The objective of this exercise was to fine tune docking parameters in
the program to identify 3001 preferentially over the false positive molecules. Two independent
trials were conducted as follows:
a. Trial 1: Unconstrained docking
b. Trial 2: Hydrogen bond constraints on the same subunit (δO of Asn 53 and backbone
carbonyl of Val 7).
The ranking of the first 20 top hits in each case is shown in Figure 3. Trial 1, in absence of any
constraints, did not lead to significant enrichment with only the experimentally verified
inhibitor (12) ranking below the false positive molecules (Figure 3a). Trial 2, where two sets
of independent hydrogen bond constraints on each subunit were used, led to a better score for
12 over all the other false positive molecules (Figure 3b). It is interesting to note that GLIDE
rejected six out of the 20 molecules when hydrogen bond constraints were used, because the
initial poses did not satisfy even weak hydrogen bonds.
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It is conceivable that if docking was carried out using the model derived constraints, it is likely
to enrich a database for molecules that would satisfy the hydrogen bonding constraints and
thereby yield molecules that are likely to function as strong pharmacological chaperones for
SOD-1. The optimized symmetric scoring function using four hydrogen bond (δO of Asn 53,
Asn 53′ and carbonyl O of Val 7 and Val 7′) constraints on both subunits was used to screen
a database of 2.2 million small drug-like molecules (details of database preparation in materials
and method section). The top 20 molecules obtained were tested for their ability to block SOD-1
aggregation. At least 14 out of these 20 molecules were found to be good inhibitors of SOD-1
aggregation carried out under experimental conditions described previously (Figure 3c). In a
control experiment, these molecules failed to block aggregation of α-synuclein, a structurally
unrelated protein, suggesting that these pharmacological chaperones are specific to SOD-1.
Most of these molecules do not bear any structural resemblance to the 12, however, they satisfy
the hydrogen bond constraints on the receptor (Figure 4 and Figure 4 supplemental).
The 14 new inhibitors of aggregation were tested for their ability to bind GST-SOD-1 in blood
plasma using the assay method described before. Control experiments were also carried out
where compound binding to GST (tag) in buffer was measured in an identical fashion. None
of the molecules exhibited any specific binding affinity towards GST. At least six out the 14
molecules exhibited significantly high specificity of binding towards SOD-1 over blood plasma
components (Figure 3d).
Discussion
We recently described a set of molecules that can bind at the SOD-1 dimer interface as
pharmacological chaperones, and block aggregation of the mutant form of the protein.
Pharmacological chaperones, unlike enzyme inhibitors, work by increasing the free energy of
unfolding of a mutant protein, and may not bind their target with high affinity. This allows
more than chemical scaffolding to satisfy the constraints necessary for a good pharmacological
chaperone. In this manuscript, we extend our previous study to develop a more generalized
method for predicting molecules that are likely to serve as good inhibitors of mutant SOD-1.
Furthermore, we use this algorithm to predict molecules that have improved binding specificity
towards SOD-1 over protein components of blood plasma.
The 11 new molecules chosen for this study typically possess either an aza-uracil or uracil
group (base pharmacophore) linked to various aromatic or aliphatic sidechains by either an
imino or thioether linker. Seven out of 14 molecules tested were found to be excellent
pharmacological chaperones effective in blocking aggregation. The highest affinity SOD-1
pharmacological chaperones in buffer may not necessarily be the ideal candidates for
administration as therapeutics in human since these molecules may bind other protein targets
in the human body. This would lead to off-pathway toxicity, as well as poor delivery to the
intended target. There is precedence for early medicinal chemistry studies to reduce off
pathway toxicity by Kelly and co-workers on pharmacological chaperones that block
aggregation of TTR54. These seven active compounds were tested for their ability to bind
SOD-1 in blood plasma. Almost all the compounds bound strongly to protein components in
blood plasma, and showed poor binding specificity towards SOD-1.
In order to understand and improve the compounds binding specificity, structural information
was necessary to identify new sites for modification on the original molecules in order to reduce
off pathway binding to blood plasma components. Docking calculations were performed to
model the aggregation inhibitors at the dimer interface binding pocket. The SOD-1 binding
pocket is largely hydrophobic in nature, composed of Val 148 and Val 7 contributed by opposite
subunits. The docked structures reveal that the aza-uracil/uracil imino groups make
electrostatic and hydrogen bonds with the backbone carbonyl of Val 7 and side chain carbonyl
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of Arg 53. The proposed model for binding of this compound was found to be consistent with
site directed mutagenesis studies and modifications of the base pharmacophore.
We carried out docking calculations on a library of ∼2.2 million molecules with four hydrogen
bond constraints (2 on Asn 53 and 2 on Val 7). The docking calculations yielded at least 20
molecules that satisfied the docking constraints (hydrogen bonds). Surprisingly, most of these
molecules had no resemblance to the original molecules (aza-uracil based), but could still make
hydrogen bonds with Asn 53 and Val 7 (see Figure 4 and Figure 4 supplemental). These
molecules were tested for their ability to block aggregation of SOD-1A4V and specifically bind
SOD-1 over blood plasma components. At least 14 out of the 20 molecules tested here were
highly effective in blocking aggregation of SOD-1A4V. We found at least six molecules that
had high specificity towards SOD-1 as well, and performed significantly better than the original
aza-uracil based molecules when tested in blood plasma.
These molecules represent a good starting point for drug development. In addition, some
optimization of their biological properties (ADME, reduced toxicity) will be required before
our working hypothesis can be tested by administering compounds in mouse models of FALS.
Nevertheless, the studies proposed here represent a critical first step in the search for an
effective ALS therapeutic. Finally, we hope that pharmaceutical companies will use the
approach described here to screen their own proprietary libraries for potential lead compounds.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
(a) Aggregation of SOD-1A4V monitored using size-exclusion chromatography in presence of
a series of compounds having either uracil or aza-uracil like substructures. The amount of dimer
observed after 48hrs of incubation is plotted after normalization of the aggregation curves.
Two molecules 4, 5 bear methylation at different positions on the aza-uracil ring and are
indicated by (*) on top of the bar chart. (b) Unfolding of SOD-1A4V measured as a function of
GdnCl. in presence of the small molecules tested in the left panel. The data have been fitted to
a two-state model to facilitate the calculation of thermodynamics parameters shown in the table
below (left). (c) Measurement of compound specificity towards a GST-SOD-1 fusion protein
(green bars) in presence of buffer and blood plasma. Control experiments include binding in
buffer (black bars) and GST (tag) alone (red bars).
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Figure 2.
(a) Docked poses for 7 of the molecules that were found to be strong inhibitors of SOD-1
aggregation described in figure 1. The dimer interface region of SOD-1 around residues 148
is shown indicating that uracil or aza-uracil substructures occupy very similar positions in all
cases, and makes hydrogen bonds with Asn 53 and Val 7. The rest of the molecules, however,
do not appear to have any preferred orientation in the dimer interface. (b) Effect of compounds
on aggregation of SOD-1A4V/N53A measured in a fashion similar to the one described in figure
1a. The mutant was generated with the rationale that N53→A should lead to the loss of a
hydrogen bond with the small molecules. The experimental data indicates minimal or no effect
on aggregation of the double mutant by the small molecules which normally stabilizes
SOD-1A4V. (c) Schematic representation of a symmetric molecule with two aza-uracil groups
bound at the dimer interface of SOD-1. The schematic representation indicates the possibility
of two pairs of hydrogen bonds between the protein and the small molecule. (d) Effect of various
concentrations of 8 or 12 on the aggregation of SOD-1A4V. 12 makes two pairs of hydrogen
and is more effective at lower concentrations compared to 8.
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Figure 3.
(a,b) Glidescores obtained after docking calculations were carried out using GLIDE with a set
of “false positive” molecules mixed with experimentally verified aggregation inhibitors. The
top panel uses standard docking parameters of the GLIDE program. The bottom panel describes
docking calculations carried out after two hydrogen bond constraints were placed on C=O of
Val 7 and the side-chain of Asn53. The use of the hydrogen bonding constraints leads to
substantial enrichment of the experimentally verified inhibitors over the false positives. (c)
Aggregation of SOD-1A4V monitored using size-exclusion chromatography in presence of a
series of compounds that were obtained after screening of a database of 2.2 million molecules
using the experimentally derived hydrogen bond constraints on Val 7 and Asn 53. The amount
of dimer observed after 48hrs of incubation is plotted after normalization of the aggregation
curves. (d) Binding of the new molecules obtained after docking and verified by aggregation
assay as inhibitors, tested in the plasma binding assay as described above. At least six molecules
show significantly improved binding specificity towards SOD-1 over blood plasma proteins.
Control experiments include binding in presence of buffer and GST (tag only). The compounds
show specificity towards binding to the GST-SOD-1 fusion protein but not towards GST (tag).
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Figure 4.
Chemical structures for the molecules that were found to have high docking scores, and satisfy
the hydrogen bonding constraints imposed by the docking program.
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Table-1
Protein/protein + compound Free Energy ΔG Kcal Mol-1 Free Energy of stabilization ΔΔG Kcal Mol-1 m value Kcal mol-1 M-1
A4V 5.25 0 4.0
WT 12.45 7.2 3.9
A4V + 1 8.56 3.31 4.2
A4V + 7 8.89 3.64 3.8
A4V + 3 10.99 5.74 4.1
A4V + 2 9.78 4.53 4.2
A4V + 9 11.09 5.84 3.8
A4V + 10 11.77 6.52 4.1
A4V + 8 10.99 5.74 3.9
A4V + 12 12.01 6.76 4.2
A4V + 14 11.99 6.74 3.8
A4V + 13 11.98 6.73 4.1
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